_										
PTO-1449			ATTY. DOCKET NO.		SERIAL NO.					
LIST OF PRIOR ART CITED BY APPLICANT			SERVIER 4	103 DIV	10/813,	347				
SHEET 1	OF	3 PE	1							
MAR 1 6 2015 STEEL TO STEEL ST			APPLICANT G. LAVIELLE, O. MULLER, M. MILLAN, and A. GOBERT							
MAR				GROUP 1625						
		C IBB	-	U.S. PA	TENT DOCUMENTS					
Examiner Initial		DOCUMENT NUMBER		DATE	NAME		CLASS	SUB- CLASS	FILING DAT APPROPRI	
-										
				FOREIGN I	PATENT DOCUMENT	S				
		DOCUMENT NUMBER		DATE	COUNTRY		CLASS	SUB- CLASS	TRANSLATIO	
									YES	NO
	,				IER PRIOR ART		1-1			
		BERENDSEN, et al., Psychopharmacology, 1990, 101, 57-61.								
		MILLAN, et al., European Journal of Pharmacology, 1997, 325, 9-12.								
!		O'NEILL, et al., Pharmacology, Biochemistry, and Behavior, 1999, 63, 237-243.								
		REAVILL, et al., British Journal of Psychopharmacology, 1999, 126, 572-574.								
		HERRICK-DAVIS, et al., Journal of Pharmacology and Experimental Therapeutics, 2000, 295, 226-232.								
		WOOD, et al., Drug Development Research, 2001, 54, 88-94.								
		PAIVA, et al., Psychopharmacology, 1988, 96, 395-399.								
		DUGOVIC, Journal Sleep Research, 1992, 1, 1163-1168.								
		LANDOLT, et	al., Neu	ropsychopha	rmacology, 1999 , 21,	455-466.				-
		SHARPLEY, et al., Biological Psychiatry, 2000, 47, 468-470.								
		WATSON, et	al., <i>Phar</i>	macology, Bi	iochemistry, and Beha	vior, 199	1, 39, 605	5-612.		
EXAMINE	R	DATE CONSI	DERED							

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO-1449	ATTY. DOCKET NO. SERVIER 403 DIV	SERIAL NO. 10/813,347		
LIST OF PRIOR ART CITED BY APPLICANT				
SHEET 2 OF 3				
	APPLICANT G. LAVIELLE, O. MULLER, M. MILLAN, and A. GOBERT			
	FILING DATE March 30, 2004	GROUP 1625		

OTHER PRIOR ART

	OTHER PRIOR ART
F	FOREMAN, et al., <i>Life Sciences</i> , 1989 , <i>45</i> , 1263-1270.
	KLINT, et al., Psychopharmacology, 1995, 119, 291-294.
	HIRSCHFELD, Journal of Clinical Psychiatry, 60 Suppl. 17:32-35, 1999.
1	POPOVA, et al., Neuroendocrinology, 2002, 76, 28-34.
,	Amesergide, LY-237733; <i>Pharmaproject</i> , Phase II Clinical Trial, 2005
	KOSKINEN, et al., Pharmacology, Biochemistry and Behavior, 2000, 66, 729-738.
,	WHITE, et al., Pharmacology, Biochemistry and Behaviour, 1991, 39, 729-736.
	MILLAN, et al., Journal of Pharmacology and Experimental Therapeutics, 2001, 298, 581-591.
<u> </u>	MUNDO, et al., International Clinical Psychopharmacology, 2000, 15, 69-76.
	MILLAN, et al., <i>Prog. Neurobiol.</i> , 1999 , <i>57</i> , 1-164.
	MILLAN, et al., <i>Prog. Neurobiol.</i> , 2002 , <i>66</i> , 355-474.
	KALKMAN, et al., Int. J. Clin. Pharmacol. Res., 1997, 17, 75-77.
	KALKMAN, et al., Naunyn Schmiedebergs. Arch. Pharmacol., 1994, 350, 225-229.
	KALKMAN, et al., <i>Life Sci.</i> , 1994 , <i>54</i> , 641-644.
	Ro-60-0759, Pharmaproject, Preclinical Trial, 2005
	SB-243213, Pharmaproject, Phase I Clinical Trial, 2005
EXAMINER	DATE CONSIDERED
*EXAMINER: Init	tial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO-1449 LIST OF PRIOR ART CITED BY APPLICANT	ATTY. DOCKET NO. SERVIER 403 DIV	SERIAL NO. 10/813,347	
SHEET 3 OF 3	APPLICANT G. LAVIELLE, O. MULLER, M. MILLAN, and A. GOBERT		
	FILING DATE March 30, 2004	GROUP 1625	

OTHER PRIOR ART

	OTTENT NONAN
	LY-053857, Pharmaproject, Phase II Clinical Trial (2005).
	KANT, Pharmacol. Biochem. Behav., 1998, 59, 729-735.
	MENESES, et al., <i>Behav. Brain Res.</i> , 1997 , <i>87</i> , 105-110.
	KANT, Pharmacol. Biochem. Behav., 1996, 53, 385-390.
	DI GIOVANNI, et al., <i>Indian J. Exp. Biol.</i> , 2002 , <i>40</i> , 1344-1352.
	DE DEURWAERDERE, et al., Trends Pharmacol. Sci., 2001, 22, 502-504.
	MILLAN, et al., Neuropharmacology, 1998, 37, 953-955.
	FOX, et al., Drug News and Perspectives, 1999, 12:477-483.
	FOX, et al., Movement Disorders, 2000, 15:1064-1069.
	SM-3163, Pharmaproject, Phase II Clinical Trial (2005).
EXAMINER	DATE CONSIDERED
*EXAMINER:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.